EUVIMEDEUVIMED entdecken
Crossref

Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma

Xiaoyi Guo, Muye Hu, Qian Zhang, Jiayue Liu, Jing Shi, Yanfang Tang, ShuHui Liu, Jun Guo, Yan Kong, Hua Zhu, Zhi Yang iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Xiaoyi Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: CD146 Antigen, Zirconium, Melanoma, Positron-Emission Tomography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Hospitals Authority Dengfeng Project, Youth Talent Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to evaluate the preclinical efficacy of [89Zr]Zr-DFO-Ab253 as a novel positron emission tomography (PET) tracer for CD146-positive malignant melanoma imaging. Considering the high expression of CD146 in malignant melanoma, this study investigated the effect of different CD146 expression levels on the tumor uptake of [89Zr]Zr-DFO-Ab253. CD146 selectivity was investigated by using the CD146-positive human melanoma cell A375 and the CD146-negative human alveolar epithelial cell A549. The cell uptake of [89Zr]Zr-DFO-Ab253 tracers was investigated, and receptor-binding affinities were measured by radioactive enzyme-linked immunosorbent assay. Biodistribution studies and micro-PET imaging of the radiotracers were performed on mice bearing A375 and A549 xenografts under baseline and blocking conditions. An immunohistochemical test was performed using A375 and A549 tissue sections for CD146 expression level analysis. [89Zr]Zr-DFO-Ab253 was obtained with a high radiochemical yield (87.86 ± 4.66%) and a satisfactory radiochemical purity (>98.0%). The specificity and affinity of [89Zr]Zr-DFO-Ab253 were confirmed in melanoma A375 cells and in vivo PET imaging of A375 tumor models. [89Zr]Zr-DFO-IgG and A549 lung tumors were prepared as control radiotracers and negative models to verify the specificity of [89Zr]Zr-DFO-Ab253 on CD146. [89Zr]Zr-DFO-Ab253 has a Kd of 4.01 ± 0.50 nM. PET imaging and biodistribution showed a higher uptake of [89Zr]Zr-DFO-Ab253 in A375 melanomas than that in A549 tumors (42.1 ± 4.04% vs 7.87 ± 1.30% ID/g at 120 h, P < 0.05). A low tumor uptake of [89Zr]Zr-DFO-IgG was observed with uptakes of 1.91 ± 0.41 and 2.80 ± 0.14 ID%/g when blocked at 120 h. The radiation-absorbed dose was calculated to be 0.13 mSv/MBq. This study demonstrates the synthesis and preclinical evaluation of [89Zr]Zr-DFO-Ab253 and indicates that the novel tracer has promising applications in malignant melanoma-specific PET imaging because of its high uptake and long-time retention in malignant melanoma. It also provides feasibility for the development of integrated molecular probes for diagnosis and treatment based on the CD146 target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD146 AntigenZirconiumMelanomaPositron-Emission TomographyAntibodies, MonoclonalRadioisotopesAnimalsHumansMiceTissue DistributionCell Line, TumorMice, NudeA549 CellsRadiopharmaceuticalsFemale

Stichwörter der Autor:innen

CD146melanomamonoclonal antibodiespositron emission computed tomographyzirconium-89

Substanzen

CD146 AntigenZirconiumZirconium-89Antibodies, MonoclonalRadioisotopesMCAM protein, humanRadiopharmaceuticals

Autor:innen und Institutionen

  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceu…
  • Guizhou University Medicine College, Guiyang 550025, Guizhou, China.
  • Multitude Therapeutics, 159 Tianzhou Road, Xuhui District, Shanghai 200030, China.
  • Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China.

ORCID-Profile: Zhi Yang

Förderung

  • National Natural Science Foundation of China
  • Beijing Hospitals Authority Dengfeng Project
  • Youth Talent Support Program
  • Pilot Project to Reform Public Development of Beijing Municipal Medical Research Institute

Zitieren

APA

Guo, X., Hu, M., Zhang, Q., Liu, J., Shi, J., Tang, Y., Liu, S., Guo, J., Kong, Y., Zhu, H., & Yang, Z. (2024). Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00348

Vancouver

Guo X, Hu M, Zhang Q, Liu J, Shi J, Tang Y, et al. Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00348

BibTeX
@article{Guo2024,
  author = {Guo, Xiaoyi and Hu, Muye and Zhang, Qian and Liu, Jiayue and Shi, Jing and Tang, Yanfang and Liu, ShuHui and Guo, Jun and Kong, Yan and Zhu, Hua and Yang, Zhi},
  title = {Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00348}
}
Kostenlos starten →